Anna Isaacs‐Ten, Marta Echeandia, Mar Moreno‐Gonzalez, Arlaine Brion, Andrew Goldson, Mark Philo, Angela M. Patterson, Aimee Parker, Mikel Galduroz, David Baker, Simon M. Rushbrook, Falk Hildebrand, Naiara Beraza – 13 March 2020
Naemat Sandhu, Victor Navarro – 13 March 2020 – Although drug‐induced liver injury (DILI) is a rare clinical event, it carries significant morbidity and mortality, leaving it as the leading cause of acute liver failure in the United States. It is one of the most challenging diagnoses encountered by gastroenterologists. The development of various drug injury networks has played a vital role in expanding our knowledge regarding drug‐related and herbal and dietary supplement–related liver injury.
Manisha Verma, Elliot B. Tapper, Amit G. Singal, Victor Navarro – 13 March 2020 – Palliative care (PC) that has evolved from a focus on end‐of‐life care to an expanded form of holistic care at an early stage for patients with serious illnesses and their families is commonly referred to as nonhospice PC (or early PC). Patients with end‐stage liver disease (ESLD) suffer from a high symptom burden and a deteriorated quality of life (QOL), with uncertain prognosis and limited treatment options.
Mussarat N. Rahim, Michael A. Heneghan – 13 March 2020
Thoetchai (Bee) Peeraphatdit, Jennifer Wang, Matthew A. Odenwald, Shaomin Hu, John Hart, Michael R. Charlton – 13 March 2020 – Immune checkpoint inhibitors (ICIs) are monoclonal antibodies targeting immune checkpoint molecules. ICIs are an immunotherapy for the treatment of many advanced malignancies. The advent of ICIs has been a major breakthrough in the field of oncology, a fact recognized by the 2018 Nobel Prize in Physiology or Medicine being awarded for the discovery.
Austin D. Schenk, W. Kenneth Washburn – 13 March 2020
Manisha Verma, Elliot B. Tapper, Amit G. Singal, Victor Navarro – 13 March 2020 – Palliative care (PC) that has evolved from a focus on end‐of‐life care to an expanded form of holistic care at an early stage for patients with serious illnesses and their families is commonly referred to as nonhospice PC (or early PC). Patients with end‐stage liver disease (ESLD) suffer from a high symptom burden and a deteriorated quality of life (QOL), with uncertain prognosis and limited treatment options.
Ghideon Ezaz, Hirsh D. Trivedi, Margery A. Connelly, Claudia Filozof, Kellie Howard, Mark L.Parrish, Misung Kim, Mark A. Herman, Imad Nasser, Nezam H. Afdhal, Z. Gordon Jiang, Michelle Lai – 13 March 2020 – Nonalcoholic fatty liver disease (NAFLD) is a heterogeneous disease driven by genetic and environmental factors. MicroRNAs (miRNAs) serve as pleiotropic post‐transcriptional regulators of cellular pathways.
Injoon Yeo, Gi‐Ae Kim, Hyunsoo Kim, Ji Hyeon Lee, Areum Sohn, Geum‐Youn Gwak, Jeong‐Hoon Lee, Young‐Suk Lim, Youngsoo Kim – 13 March 2020 – There is an urgent need for new biomarkers that address the shortcomings of current screening methods which fail to detect a large proportion of cases with hepatocellular carcinoma (HCC) at early stage. To develop a robust, multiple‐biomarker panel based on multiple reaction monitoring–mass spectrometry with high performance in detecting early‐stage HCC within at‐risk populations.
Manisha Verma, Elliot B. Tapper, Amit G. Singal, Victor Navarro – 13 March 2020 – Palliative care (PC) that has evolved from a focus on end‐of‐life care to an expanded form of holistic care at an early stage for patients with serious illnesses and their families is commonly referred to as nonhospice PC (or early PC). Patients with end‐stage liver disease (ESLD) suffer from a high symptom burden and a deteriorated quality of life (QOL), with uncertain prognosis and limited treatment options.